News und Analysen
Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
CI Financial Reports Record Total Assets of $400.9 Billion for May 2023
CI Financial Corp. (“CI”) (TSX: CIX) today reported preliminary total assets of $400.9 billion as at May 31, 2023, representing a record for the firm. Total assets consisted of asset management
EQS-News: Medios AG: Annual General Meeting re-elects Dr. Yann Samson, Joachim Messner and Klaus J. Buß to the Supervisory Board
OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Company has received €1.5 million in non-dilutive funding from Bpifrance - Direction
EQS-News: Medios AG centralizes blister business at one site and sells Kölsche Blister GmbH
Granite REIT Declares Distribution for June 2023
Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) announced today that its board of trustees has declared a distribution of CDN $0.2667 per stapled unit for the month of
Vistagen to Participate in the Maxim Group Healthcare Virtual Conference Hosted by M-Vest
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
CI Financial Renews Normal Course Issuer Bid and Automatic Securities Purchase Plan
CI Financial Corp. (“CI”) (TSX: CIX) announced today that the Toronto Stock Exchange (“TSX”) has accepted its Notice of Intention to make a Normal Course Issuer Bid and Automatic Securities
CI Global Asset Management Announces June 2023 Distributions for CI ETFs
CI Global Asset Management (“CI GAM”) announces the following regular cash distributions for the month or quarter ending June 30, 2023 in respect of the CI ETFs. In all cases, the distribution will
OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presents scientific updates in oral and poster presentations selected for international conferences: at the Antibody
Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Mannatech Announces Results of Annual Shareholders’ Meeting
Mannatech, Incorporated (Nasdaq: MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all
Granite REIT Announces Voting Results From Its 2023 Joint Annual General Meetings of Stapled Unitholders
Granite Real Estate Investment Trust (“Granite REIT”) and Granite REIT Inc. (“Granite GP”) (collectively “Granite”) (TSX: GRT.UN / NYSE: GRP.U) announced today the results of the matters voted on
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Vistagen to Present at Jefferies 2023 Global Healthcare Conference
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Vistagen Announces Stockholder-Approved Reverse Stock Split
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented a poster and a publication in abstract book featuring Tedopi®, an immunotherapy activating tumor specific
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
EQS-News: Medios AG: Supervisory Board extends contract with Chief Financial Officer Falk Neukirch
Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Mannatech Declares First Quarter 2023 Dividend
Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, announced that its Board of Directors declared a cash dividend
CI Financial Corp. Announces Completion of Debt Tender Offers and Pre-IPO Minority Investment in Its U.S. Wealth Management Business
CI Financial Corp. (“CI”) (TSX: CIX) today announced that it has repurchased $234,775,000 of its outstanding 3.215% Debentures due 2024, $370,762,000 of its outstanding 3.759% Debentures due 2025
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Mannatech Announces New Tiered Affiliate Program Pre-Launch
Mannatech, Incorporated (NASDAQ: MTEX), a leading nutritional supplement company, has announced that it anticipates launching its new tiered affiliate program on June 16, 2023. As previously
CI Financial Reports Record Total Assets of $394.9 Billion for April 2023
CI Financial Corp. (“CI”) (TSX: CIX) today reported preliminary total assets of $394.9 billion as at April 30, 2023, a record for CI. The total consisted of asset management assets of $123.4